GlobeNewswire
-
Instil Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update
16/11/2026 -
ToltIQ Chooses ABBYY for Parsing Complex Deal Documents
16/11/2026 -
GT Biopharma Reports Third Quarter 2026 Financial Results
16/11/2026 -
Lumexa Imaging Opens Three New Imaging Centers in November
16/11/2026 -
Invivyd Reports Third Quarter 2026 Financial Results and Recent Business Highlights
16/11/2026 -
Prelude Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
16/11/2026 -
Roche’s Gazyva/Gazyvaro becomes the first FDA-approved treatment for primary membranous nephropathy
16/11/2026 -
Lakefront Initiates New €50 Million Share Repurchase Program Following Completion of Initial Share Repurchase Program
16/11/2026 -
FOR INVESTORS AND FINANCIAL AND BUSINESS MEDIA ONLY Renaissance Pharma secures FDA Breakthrough Therapy Designation for daretabart in newly diagnosed high-risk neuroblastoma
16/11/2026 -
Oculis Announces FDA IND Clearance Enabling Acceleration of Privosegtor Development Program in Acute Multiple Sclerosis Relapses
16/11/2026 -
Relmada Therapeutics Appoints Uro-Oncology Leader Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer
16/11/2026 -
Oculis Announces FDA IND Clearance Enabling Acceleration of Privosegtor Development Program in Acute Multiple Sclerosis Relapses
16/11/2026 -
RAMSAY SANTE : nouvelle gouvernance
16/11/2026 -
RAMSAY SANTE : new governance
16/11/2026 -
Philips to nominate Dick Boer, Laurence Debroux and Todd Brinton to its Supervisory Board at the 2027 Annual General Meeting of Shareholders (AGM)
16/11/2026 -
Rejuvenate Biomed Completes Last Patient Visit in Phase 2 Trial of RJx-01 in COPD-Related Muscle Weakness and Advances Regulatory Discussions for Sarcopenia
16/11/2026 -
Aclaris Therapeutics Announces Top Line Phase 2 Results for its Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) in Atopic Dermatitis (AD)
16/11/2026 -
Aclaris Therapeutics Initiates Phase 2b Trial of Modzatinib (ATI-2138) in Lichen Planus (LP)
16/11/2026 -
NTG Nordic Transport Group A/S – Capital Markets Day Agenda
16/11/2026
Pages